SCHEMBL5230507

SCHEMBL5230507

O=C1CCN(Cc2cccc3ccccc23)C(=O)[C@H](Cc2csc3ccccc23)N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ SSTR1 P30872 2/20 0.41
▸ SSTR2 P30874 2/20 0.41
▸ SSTR4 P31391 2/20 0.41
▸ SSTR3 P32745 2/20 0.41
▸ SSTR5 P35346 2/20 0.41
▸ CHRNA7 P36544 1/20 0.40
▸ CRHBP P24387 1/20 0.40
▸ CRHR2 Q13324 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ DRD2 P14416 2/20 0.38
▸ DRD4 P21917 2/20 0.38
▸ DRD3 P35462 2/20 0.38
▸ ACHE P22303 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5234092 0.81 KMT2A (0.67) MAPTMEN1KMT2ASSTR1SSTR2
SCHEMBL5239008 0.80 CLPP (0.42) MAPTMEN1KMT2ASSTR1SSTR2
SCHEMBL7094153 0.78 L3MBTL1 (0.43) MAPTMEN1KMT2ASSTR1SSTR2
SCHEMBL5229554 0.77 TACR2 (0.43) MAPTMEN1KMT2ASSTR1SSTR2
SCHEMBL5232940 0.77 TACR2 (0.43) MAPTMEN1KMT2ASSTR1SSTR2
SCHEMBL7830077 0.76 OPRK1 (0.56) MEN1KMT2ACHRNA7CRHBPCRHR2
SCHEMBL874098 0.70 OPRK1 (0.65) MAPTMEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL874099 0.70 OPRK1 (0.65) MAPTMEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL7468758 0.70 OPRK1 (0.65) MAPTMEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL836661 0.70 RIPK1 (0.51) MAPTMEN1KMT2ACHRNA7CRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452001-B2 1,4-DIAZEPINE-2-ONE DERIVATIVES AS NEUROKININ ANTAGONIST HOFFMANN-LA ROCHE INC. 2002-09-17 — — US claimed
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — US claimed
EP-1296961-B1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2007-02-14 — — EP disclosed
US-6452001-B2 1,4-DIAZEPINE-2-ONE DERIVATIVES AS NEUROKININ ANTAGONIST HOFFMANN-LA ROCHE INC. 2002-09-17 — — US disclosed
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation BDKRB2, NPSR1, BDKRB1 MAPT 4885/4885MEN1 687/4885KMT2A 1204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback